Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier

Journal of Drug Targeting

Volumn 18, Issue 1, 2010, Pages 53-58

  Mooberry, Linda K ^a   Nair, Maya ^a   Paranjape, Sulabha ^a   McConathy, Walter J ^b   Lacko, Andras G ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Folate receptor; Lipid nanoparticles; Lipoprotein; Paclitaxel; Receptor uptake; Targeted drug delivery

Indexed keywords

HIGH DENSITY LIPOPROTEIN; NANOCARRIER; PACLITAXEL; SCAVENGER RECEPTOR BI;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; MALE; NANOPARTICLES; PACLITAXEL; PROSTATIC NEOPLASMS; SCAVENGER RECEPTORS, CLASS B;

EID: 72749122051     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903156419     Document Type: Article

References (31)

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. (1996). Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 271, 518-520.
2. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-B1, a CD36 - related class B Scavenger receptor. Journal of Biological Chemistry, 269, 21003-21009. Line 55, Page 5.
3. Arenas MI, Lobo MV, Caso E, Huerta L, Paniagua R, Martin- Hidalgo MA. (2004). Normal and pathological human testes express hormone-sensitive lipase and the lipid receptors CLA-1/ SR-BI and CD36. Hum Pathol, 35, 34-42.
4. Benoist F, Lau P, McDonnell M, Doelle H, Milne R, McPherson R. (1997). Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue. J Biol Chem, 272, 23572-23577.
5. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, Niimi M, Miyauchi A, Wong NC, Ishida T. (2004). A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res, 64, 1515-1521.
6. Corbin IR, Zheng G. (2007). Mimicking nature's nanocarrier: Synthetic lowdensity lipoprotein-like nanoparticles for cancer-drug delivery. Nanomedicine, 2, 375-380.
7. Counsell RE, Pohland RC. (1982). Lipoproteins as potential site- specific delivery systems for diagnostic and therapeutic agents. J Med Chem, 25, 111-125.
8. Das M, Mohanty C, Sahoo SK. (2009). Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv, 6, 285-304.
9. Dessi S, Batetta B, Pulisci D, Accogli P, Pani P, Broccia G. (1991). Total and HDL cholesterol in human hematologic neoplasms. Int J Hematol, 54, 483-486.
10. Fenske DB, Chonn A, Cullis PR. (2008). Liposomal nanomedicines: An emerging field. Toxicol Pathol, 36, 21-29.
11. Fiorenza AM, Branchi A, Sommariya D. (2000). Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res, 30, 141-145.
12. Hamilton SR. (2008). Targeted therapy of cancer: New roles for pathologists in colorectal cancer. Mod Pathol, 21(Suppl. 2), S23-S30.
13. Kelley JL, Kruski AW. (1986). Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor. Methods Enzymol, 128, 170-181.
14. Lacko AG, Nair M, Paranjape S, Johnson S, McConathy WJ. (2002). High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res, 22, 2045-2049.
15. Lacko AG, Nair M, Paranjape S, Mooberry L, McConathy WJ. (2006). Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy, 52, 171-173.
16. Lacko AG, Nair M, Prokai L, McConathy WJ. (2007). Prospects and challenges of the development of lipoprotein based drug formulations for anti-cancer drugs. Expert Opin Drug Deliv, 4, 665-675.
17. Lacko AG, Shahzad S, Nair M, Mangala LS, McConathy WJ, Lopez- Berestein G, Sood AK. (2009). Targeted delivery of drugs via biocompatible nanoparticles (Abstract). NanoIsrael, Jerusalem, Israel.
18. Leamon CP, Low PS. (1993). Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem J, 291, 855-860.
19. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs, 19, 183-188.
20. Markel A, Brook GJ. (1994). Cancer and hypocholesterolemia. Isr J Med Sci, 30, 787-793.
21. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. (2007a). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm, 328, 86-94. (Pubitemid 44827556)
22. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. (2007b). Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Rel, 124, 163-171. (Pubitemid 350101886)
23. Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, Sattler W. (2000). The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)- mediated selective cholesteryl ester uptake. Biochem J, 349, 559-566.
24. Redgrave TG, Roberts DC, West CE. (1975). Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem, 65, 42-49.
25. Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ. (2008). Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol, 111, 461-466.
26. Vitols S. (1991). Uptake of low-density lipoprotein by malignant cells-possible therapeutic applications. Cancer Cells, 3, 488-495.
27. Vitols S, Angelin B, Ericsson S, Gahrton G, Juliusson G, Masquelier M, Paul C, Peterson C, Rudling M, Söderberg-Reid K, Tidefelt U. (1990). Uptake of low density lipoproteins by human leukemic cells in vivo: Relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA, 87, 2598-2602.
28. Wadsack C, Hrzenjak A, Hammer A, Hirschmugl B, Levak-Frank S, Desoye G, Sattler W, Malle E. (2003). Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. Eur J Biochem, 35, 451-462.
29. Weitman, SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA (1992). Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res, 52, 3396-3401.
30. Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y. (2008). Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res, 14, 8161-8168.
31. Zheng G, Chen J, Li H, Glickson JD. (2005). Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA, 102, 17757-17762.